Your browser doesn't support javascript.
loading
Modulating sphingosine-1-phosphate receptors to improve chemotherapy efficacy against Ewing sarcoma.
Marmonti, Enrica; Savage, Hannah; Zhang, Aiqian; Bedoya, Claudia A F; Morrell, Miriam G; Harden, Avis; Buzbee, Meridith; Schadler, Keri.
Afiliação
  • Marmonti E; Department of Pediatric Research, MD Anderson Cancer Center, Houston, TX.
  • Savage H; Department of Pediatric Research, MD Anderson Cancer Center, Houston, TX.
  • Zhang A; Department of Pediatric Research, MD Anderson Cancer Center, Houston, TX.
  • Bedoya CAF; Department of Gynecology, Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
  • Morrell MG; Department of Pediatric Research, MD Anderson Cancer Center, Houston, TX.
  • Harden A; Department of Pediatrics, MD Anderson Cancer Center, Houston, TX.
  • Buzbee M; Department of Pediatrics, MD Anderson Cancer Center, Houston, TX.
  • Schadler K; Department of Pediatric Research, MD Anderson Cancer Center, Houston, TX.
Int J Cancer ; 147(4): 1206-1214, 2020 08 15.
Article em En | MEDLINE | ID: mdl-31922252
ABSTRACT
Tumor vasculature is innately dysfunctional. Poorly functional tumor vessels inefficiently deliver chemotherapy to tumor cells; vessel hyper-permeability promotes chemotherapy delivery primarily to a tumor's periphery. Here, we identify a method for enhancing chemotherapy efficacy in Ewing sarcoma (ES) in mice by modulating tumor vessel permeability. Vessel permeability is partially controlled by the G protein-coupled Sphinosine-1-phosphate receptors 1 and 2 (S1PR1 and S1PR2) on endothelial cells. S1PR1 promotes endothelial cell junction integrity while S1PR2 destabilizes it. We hypothesize that an imbalance of S1PR1S1PR2 is partially responsible for the dysfunctional vascular phenotype characteristic of ES and that by altering the balance in favor of S1PR1, ES vessel hyper-permeability can be reversed. In our study, we demonstrate that pharmacologic activation of S1PR1 by SEW2871 or inhibition of S1PR2 by JTE-013 caused more organized, mature and functional tumor vessels. Importantly, S1PR1 activation or S1PR2 inhibition improved antitumor efficacy. Our data suggests that pharmacologic targeting of S1PR1 and S1PR2 may be a useful adjuvant to standard chemotherapy for ES patients.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxidiazóis / Pirazóis / Piridinas / Sarcoma de Ewing / Tiofenos / Neoplasias Ósseas / Doxorrubicina / Receptores de Esfingosina-1-Fosfato Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxidiazóis / Pirazóis / Piridinas / Sarcoma de Ewing / Tiofenos / Neoplasias Ósseas / Doxorrubicina / Receptores de Esfingosina-1-Fosfato Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article